ZYBERNO
Stock Report
Updated Sep 1, 2026

MARIMED INC. (MRMD)

Healthcare • OTC

$0.08

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
9.0/100
POOR BUSINESS
MARIMED INC. (MRMD) scores 9/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
MARGIN OF SAFETY
Is this stock cheap or expensive relative to what the business has historically generated for owners?
+78.6%
Undervalued
Growth gap unavailable — insufficient data for reverse DCF calculation.
🎯 Expected Annual Return
64.3%
Margin of Safety convergence — your return if the market re-prices to intrinsic value (5-yr annualised)
17.5%
Yield + growth — what the business alone earns you, even if the market never re-rates
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-31.2%)
Debt-to-Equity (Solvency Risk):CRITICAL (2.10x)
Operating Margin (Operational Efficiency):CRITICAL (-1.6%)
Return on Capital (Capital Efficiency):CRITICAL (-1.6%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

MARIMED INC. (MRMD) stock report — Zyberno Score 9/100 (POOR BUSINESS), Margin of Safety +78.6%, 64% expected annual return. Full financial analysis on Zyberno.

According to Zyberno's DCF model, MARIMED INC. (MRMD) trades at $0.08 against an estimated intrinsic value per share of $0.38 — a +78.6% Margin of Safety based on Owner Earnings of $6.08M TTM, projected at 15.3% growth for 10 years with a 2.5% terminal growth rate. Zyberno's model translates this into a 5-year expected return of 64.3% annually.

Over the trailing twelve months, MRMD generated $6.08M in Owner Earnings. Capital was deployed as follows: $1.27M invested in capital expenditures. Reinvestment rate: 372.6%. Owner Earnings have grown at 15.3% annually over the trailing five years using log-linear regression.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.08
Market Cap:$32.57M

Valuation Multiples (3)

P/B Ratio:0.75x
P/S Ratio:0.20x
Peg Ratio:-999.00x

Enterprise Metrics (3)

Enterprise Value:$110.67M
Ev Ebitda Ratio:7.77x
Pfcf Ratio:4.27x

Price Action & Momentum (3)

Momentum Percentile:39 / 100
% of 52-Week High:35.4%
B. Profitability Assessment

Return Metrics (5)

ROA:-7.5%
Reinvestment Rate:372.6%
Fundamental Growth Rate (g):-5.9%

Margin Analysis (3)

Operating Margin Ttm:-1.6%
Net Margin Ttm:-9.2%
Ebitda Margin:8.7%

TTM Performance (3)

Gross Margin Ttm:35.6%
Operating Margin Ttm:-1.6%
Net Margin Ttm:-9.2%

Yield Metrics (3)

Earnings Yield:-$76.92
Owner Earnings Yield:$23.40
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-77.8%
Latest Earnings Filed:2026-08-13

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):4.6%

Cash Flow Growth (Linear) (2)

Free Cash Flow Growth Rate (Linear):-4.7%
Operating Cash Flow Growth Rate (Linear):-24.1%

Operating Growth (Linear) (1)

Operating Income Growth Rate (Linear):-50.0%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.92x
Quick Ratio:0.34x
Cash Ratio:0.10x

Leverage Analysis (3)

Debt To Equity Ttm:2.10x
Debt-to-Equity Ratio:2.10x
Debt To Ebitda:5.95x

Coverage Ratios (2)

Interest Coverage Ratio:-0.35x
Times Interest Earned:-0.35

Capital Structure (4)

Working Capital:-5,320,000.00
Cash And Cash Equivalents:6,596,000.00
Long Term Debt:$82.67M
Net Debt:$78.10M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $163.67M
Linear Growth: 4.6%
📊 Click to view full MRMD Revenue analysis & methodology →
Cost Of Revenue Ttm:$105.45M

Profitability Breakdown (2)

Gross profit TTM: $58.21M
Linear Growth: -3.8%
📊 Click to view full MRMD Gross Profit analysis & methodology →
Operating income TTM: -$2.57M
Linear Growth: -50.0%
📊 Click to view full MRMD Operating Income analysis & methodology →

Bottom Line Performance (3)

-$15.14M
Income Before Tax:-$10.36M
Ebitda Ttm:14,241,000.00

Operating Expenses (5)

Operating Expenses:60,779,000.00
R And D Expense:0.00
Sga Expense:27,300,000.00
Income Tax Expense:$8.26M
Interest Expense:7,961,000.00

Expense Ratios (3)

R And D To Revenue Percentage:0.0%
Sga To Revenue Percentage:65.1%
Ebitda Margin:8.7%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$197.23M
Current Assets:$58.43M
Ppe Net:86,411,000.00
Goodwill:24,002,000.00
Intangible Assets:$15.68M

Liability Structure (4)

Total Liabilities:147,056,000.00
Current Liabilities:63,753,000.00
Long Term Debt:$82.67M
Short Term Debt:$2.03M

Equity & Capital (3)

Equity:$43.24M
Retained Earnings:-$135.31M
Common Stock:700,000,000.00

Working Capital Items (3)

Accounts Receivable:9,358,000.00
Inventory:36,675,000.00
Accounts Payable:13,147,000.00

Special Items (2)

Contract Liabilities:1,711,000.00
Stock Based Compensation:325,000.00
C. Cash Flow Analysis

Operating Activities (2)

Operating cash flow TTM: $7.35M
Linear Growth: -24.1%
Free cash flow TTM: $6.08M
Linear Growth: -4.7%
📊 Click to view full MRMD Free Cash Flow analysis & methodology →

Investment Activities (2)

Investing Cash Flow:-$753.00K
Capital Expenditures Ttm:1,274,000.00

Financing Activities (3)

Financing Cash Flow:-$1.14M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:16,808,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.05
-$0.05
Earnings Per Share Ttm:-$0.04

Revenue & Cash Per Share (3)

Sales Per Share Ttm:0.41
Operating Cash Flow Per Share:$0.02
Fcf Per Share Ttm:0.02

Book Value & Capital (2)

Book Value Per Share:$0.11
Cash Per Share:0.02

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.81x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:17.49x
Days Sales Outstanding Ttm:20.87

Inventory Management (2)

Inventory Turnover Ttm:2.88x
Days Inventory Outstanding Ttm:126.94

Payables & Cash Cycle (2)

Days Payable Outstanding:45.50
Cash Conversion Cycle:102.31
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:0.00
Quality Score:25.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (3)

Owner earnings TTM: $6.08M
Linear Growth: 15.3%
📊 Click to view full MRMD Owner Earnings analysis & methodology →
Owner Earnings Per Share:$0.02
Owner Earnings Yield:$23.40

Growth Assessment (1)

Owner Earnings Growth Rate:$15.31

Damodaran Growth Analysis (2)

Reinvestment Rate:372.6%
Fundamental Growth Rate (g):-5.9%

Intrinsic Value Models (1)

Return Scenarios (2)

Investment Assessment (1)

Buffett Assessment:Excellent margin of safety
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (2)

Revenue Growth Rate (Linear):4.6%
Operating Income Growth Rate (Linear):-50.0%

Cash Flow Growth Rates (2)

Free Cash Flow Growth Rate (Linear):-4.7%
Operating Cash Flow Growth Rate (Linear):-24.1%

Other Growth Rates (3)

Gross Profit Growth Rate (Linear):-3.8%
Book Value Growth Rate (Linear):-2.5%
Owner Earnings Growth Rate:$15.31
C. Company Profile & Context

Corporate Information (6)

Symbol:MRMD
Company Name:MARIMED INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:OTC
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:399.60M
Shares Outstanding Basic:399.60M
Shares Outstanding Diluted:399.60M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 08:27:05 UTC
Data Timestamp:2026-08-20T21:29:48.099524
Scroll to Top